Payment overview · 2025
General Payments
$1,922.86
98 reported records · 17 companies
Healthcare provider profile · identity verified
Adam J Prawer, MD
Allopathic & Osteopathic Physicians|Family Medicine · ST PETERSBURG, FL · NPI 1841594801
Verified facts
What the public records show
CMS Open Payments records show Adam J Prawer, MD received $1,922.86 in general payments during 2025 across 98 reported records.
Sumitomo Pharma America, Inc. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Synthroid, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 992 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $243.54 | 12.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $221.38 | 11.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.67 | 10.6% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.03 | 9.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.67 | 9.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $160.41 | 8.3% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.99 | 8.3% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $141.04 | 7.3% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.78 | 7.1% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $61.81 | 3.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.78 | 2.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.38 | 2.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.83 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.79 | 1.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.29 | 1.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.69 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.78 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,918.01 | 97 |
| Education | $4.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $243.54 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $178.01 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $173.83 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $135.78 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.43 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $129.43 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.69 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $115.36 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.36 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.15 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.99 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.70 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.96 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.99 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $75.67 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $61.97 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.24 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.78 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.12 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.29 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 992 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 92 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 169 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 99 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
169 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
992 | 191 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
95 | 92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2329 | 557 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1739 | 368 |
| Amlodipine Besylate | Amlodipine Besylate | 1355 | 323 |
| Lisinopril | Lisinopril | 1313 | 307 |
| Losartan Potassium | Losartan Potassium | 1008 | 254 |
| Eliquis | Apixaban | 992 | 191 |
| Pantoprazole Sodium | Pantoprazole Sodium | 928 | 229 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 831 | 245 |
| Gabapentin | Gabapentin | 733 | 171 |
| Trazodone Hcl | Trazodone Hcl | 731 | 175 |
| Furosemide | Furosemide | 681 | 166 |
| Omeprazole | Omeprazole | 678 | 169 |
| Hydrochlorothiazide | Hydrochlorothiazide | 677 | 174 |
| Metoprolol Succinate | Metoprolol Succinate | 650 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 628 | 156 |
| Carvedilol | Carvedilol | 566 | 114 |
| Escitalopram Oxalate | Escitalopram Oxalate | 553 | 118 |
| Simvastatin | Simvastatin | 512 | 115 |
| Tramadol Hcl | Tramadol Hcl | 501 | 165 |
| Clopidogrel | Clopidogrel Bisulfate | 481 | 116 |
| Metoprolol Tartrate | Metoprolol Tartrate | 479 | 139 |
| Lorazepam | Lorazepam | 465 | 130 |
| Metformin Hcl | Metformin Hcl | 427 | 121 |
| Citalopram Hbr | Citalopram Hydrobromide | 407 | 101 |
| Azithromycin | Azithromycin | 404 | 323 |
| Alprazolam | Alprazolam | 403 | 95 |
| Potassium Chloride | Potassium Chloride | 402 | 84 |
| Donepezil Hcl | Donepezil Hcl | 396 | 72 |
| Sertraline Hcl | Sertraline Hcl | 386 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 376 | 99 |
| Allopurinol | Allopurinol | 343 | 85 |
| Pregabalin | Pregabalin | 337 | 68 |
| Montelukast Sodium | Montelukast Sodium | 332 | 71 |
| Famotidine | Famotidine | 322 | 102 |
| Spironolactone | Spironolactone | 308 | 86 |
| Quetiapine Fumarate | Quetiapine Fumarate | 295 | 61 |
| Memantine Hcl | Memantine Hcl | 287 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 254 | 65 |
| Mirtazapine | Mirtazapine | 249 | 74 |
| Levetiracetam | Levetiracetam | 240 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 109 |
| Xarelto | Rivaroxaban | 222 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 216 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 212 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 210 | 51 |
| Divalproex Sodium | Divalproex Sodium | 209 | 41 |
| Atenolol | Atenolol | 207 | 56 |
| Myrbetriq | Mirabegron | 202 | 42 |
| Prednisone | Prednisone | 196 | 68 |
| Finasteride | Finasteride | 195 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 194 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 192 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 191 | 53 |
| Baclofen | Baclofen | 186 | 62 |
| Meloxicam | Meloxicam | 185 | 56 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 172 | 116 |
| Nystatin | Nystatin | 171 | 84 |
| Alendronate Sodium | Alendronate Sodium | 170 | 46 |
| Nifedipine Er | Nifedipine | 169 | 45 |
| Synthroid | Levothyroxine Sodium | 169 | 42 |
| Jardiance | Empagliflozin | 162 | 34 |
| Latanoprost | Latanoprost | 159 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 157 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 157 | 90 |
| Clonazepam | Clonazepam | 152 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 149 | 123 |
| Cefdinir | Cefdinir | 147 | 123 |
| Methylprednisolone | Methylprednisolone | 142 | 110 |
| Doxazosin Mesylate | Doxazosin Mesylate | 140 | 30 |
| Ozempic | Semaglutide | 139 | 32 |
| Buspirone Hcl | Buspirone Hcl | 137 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 134 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 133 | 22 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 133 | 44 |
| Methenamine Hippurate | Methenamine Hippurate | 127 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 23 |
| Temazepam | Temazepam | 124 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 121 | 35 |
| Lovastatin | Lovastatin | 117 | 27 |
| Bumetanide | Bumetanide | 114 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 109 | 17 |
| Januvia | Sitagliptin Phosphate | 107 | 16 |
| Mounjaro | Tirzepatide | 105 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 104 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 104 | 22 |
| Ibuprofen | Ibuprofen | 102 | 39 |
| Valsartan | Valsartan | 102 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 28 |
| Celecoxib | Celecoxib | 95 | 28 |
| Paxlovid | Nirmatrelvir/Ritonavir | 95 | 92 |
| Metformin Hcl Er | Metformin Hcl | 94 | 24 |
| Lamotrigine | Lamotrigine | 93 | 15 |
| Gemtesa | Vibegron | 92 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 66 |
| Warfarin Sodium | Warfarin Sodium | 91 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 26 |
| Cephalexin | Cephalexin | 87 | 61 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 25 |
| Acyclovir | Acyclovir | 84 | 30 |
| Bupropion Hcl Sr | Bupropion Hcl | 84 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 20 |
| Ezetimibe | Ezetimibe | 81 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Digoxin | Digoxin | 79 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 64 |
| Diazepam | Diazepam | 76 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 75 | 23 |
| Calcitriol | Calcitriol | 74 | 13 |
| Risperidone | Risperidone | 73 | 16 |
| Propranolol Hcl | Propranolol Hcl | 71 | 11 |
| Bupropion Xl | Bupropion Hcl | 69 | 30 |
| Lubiprostone | Lubiprostone | 69 | 11 |
| Amoxicillin | Amoxicillin | 67 | 50 |
| Methocarbamol | Methocarbamol | 67 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 66 | 11 |
| Linzess | Linaclotide | 64 | 21 |
| Midodrine Hcl | Midodrine Hcl | 64 | 26 |
| Meclizine Hcl | Meclizine Hcl | 61 | 33 |
| Diltiazem Hcl | Diltiazem Hcl | 60 | 15 |
| Lactulose | Lactulose | 60 | 16 |
| Sotalol | Sotalol Hcl | 60 | suppressed |
| Estradiol | Estradiol | 59 | 17 |
| Ketoconazole | Ketoconazole | 59 | 23 |
| Valacyclovir | Valacyclovir Hcl | 59 | 27 |
| Farxiga | Dapagliflozin Propanediol | 56 | 18 |
| Clonidine Hcl | Clonidine Hcl | 55 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 53 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 53 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 16 |
| Ramipril | Ramipril | 51 | 15 |
| Timolol Maleate | Timolol Maleate | 51 | 12 |
| Hydrocortisone | Hydrocortisone | 50 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | suppressed |
| Glimepiride | Glimepiride | 47 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 32 |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Irbesartan | Irbesartan | 44 | suppressed |
| Naproxen | Naproxen | 44 | 12 |
| Morphine Sulfate | Morphine Sulfate | 43 | 26 |
| Primidone | Primidone | 43 | 13 |
| Santyl | Collagenase Clostridium Hist. | 43 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Creon | Lipase/Protease/Amylase | 40 | suppressed |
| Ofloxacin | Ofloxacin | 40 | 37 |
| Procrit | Epoetin Alfa | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 12 |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | 16 |
| Mupirocin | Mupirocin | 36 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 25 |
| Ammonium Lactate | Ammonium Lactate | 35 | 16 |
| Dexamethasone | Dexamethasone | 35 | 23 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 16 |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 12 |
| Insulin Lispro | Insulin Lispro | 31 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Topiramate | Topiramate | 30 | suppressed |
| Anastrozole | Anastrozole | 29 | suppressed |
| Lumigan | Bimatoprost | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Belsomra | Suvorexant | 27 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 27 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 27 | 27 |
| Rivastigmine | Rivastigmine Tartrate | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 20 |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Zonisamide | Zonisamide | 25 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 14 |
| Ramelteon | Ramelteon | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | 13 |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Permethrin | Permethrin | 22 | 15 |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Meropenem | Meropenem | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 14 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Colchicine | Colchicine | 19 | 12 |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | 14 |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 17 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Rytary | Carbidopa/Levodopa | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Rhopressa | Netarsudil Mesylate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lyrica | Pregabalin | 14 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Methazolamide | Methazolamide | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Concerta | Methylphenidate Hcl | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,922.86 · 98 records | Sumitomo Pharma America, Inc. | AIRSUPRA, Auvelity, CAPLYTA, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, KISUNLA, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error